Multivariate analyses of 11 biomarkers with three clinicopathological characteristics for RFS in cohort 2 (n=314)
| Variables | RFS | |
| HR (95% CI) | p Value | |
| GGT (>54 U/l vs ≤54 U/l) | 1.62 (1.18 to 2.23) | 0.003 |
| Tumour number (multiple vs single) | 1.41 (0.94 to 2.14) | 0.101 |
| Vascular invasion (yes vs no) | 1.70 (1.11 to 2.60) | 0.014 |
| CK7 (positive vs negative) | 0.78 (0.47 to 1.30) | 0.344 |
| CK19 (positive vs negative) | 1.09 (0.64 to 1.83) | 0.756 |
| EPCAM (positive vs negative) | 1.41 (0.92 to 2.16) | 0.119 |
| ABCG2 (positive vs negative) | 1.29 (0.89 to 1.88) | 0.182 |
| OV6 (positive vs negative) | 1.05 (0.75 to 1.48) | 0.761 |
| CD133 (positive vs negative) | 1.65 (1.04 to 2.60) | 0.033 |
| Nestin (positive vs negative) | 1.48 (1.05 to 2.09) | 0.025 |
| CD44 (positive vs negative) | 2.04 (1.44 to 2.90) | <0.0001 |
| MVD (>55.5 vs ≤55.5) | 2.62 (1.85 to 3.69) | <0.0001 |
| VEGF (positive vs negative) | 0.99 (0.69 to 1.42) | 0.961 |
| PD-ECGF (positive vs negative) | 1.12 (0.77 to 1.63) | 0.558 |
Multivariate analyses, Cox proportional hazards regression model. The clinicopathological variables were adopted for their prognostic significance by univariate analyses.
ABCG2, ATP-binding cassette subfamily G member 2; CK7, cytokeratin 7; CK19, cytokeratin 19; EPCAM, epithelial cell adhesion molecule; GGT, γ-glutamyl transferase; MVD, microvessel density; PD-ECGF, platelet derived endothelial cell growth factor; RFS, relapse-free survival; VEGF, vascular endothelial growth factor.